Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 8980 results

  1. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

  2. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 April 2026.

  3. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026

  4. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 11 May 2026.

  5. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 28 April 2026.

  6. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Awaiting development Reference number: GID-TA11956 Expected publication date: TBC

  7. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

  8. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

  9. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date:  05 June 2026

  10. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    Awaiting development Reference number: GID-TA11199 Expected publication date: TBC

  11. Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]

    Awaiting development Reference number: GID-TA11935 Expected publication date: TBC

  12. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 February 2027

  13. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTE10090 Expected publication date:  10 March 2027

  14. Cervical ripening ballon for the induction of labour in women who have previously undergone cesarean section

    Topic prioritisation